<DOC>
	<DOCNO>NCT00515268</DOCNO>
	<brief_summary>The propose study examine effect pre-treatment inhale GSK256066 use lung inflammation model induce bronchoscopic instillation bacterial endotoxin ( lipopolysaccharide , LPS ) healthy volunteers.Data study use support GSK256066 dose selection future study COPD patient .</brief_summary>
	<brief_title>Endotoxin Challenge Study For Healthy Men Women</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>Healthy male female ( contraception restriction ) , 1850yrs , BMI 1931kg/m2 , Nonsmokers , FEV1 &gt; /= 80 % predict Abnormal troponin and/or CK MB , Participated GSK study involve administration COA &gt; /= 21 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>LPS challenge ,</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>